ARC Group Joins BFSU University-Enterprise Cooperation Alliance for Study in China

ARC Group Joins BFSU University-Enterprise Cooperation Alliance for Study in China

ARC Group proudly announces its recent inclusion as a board member in the prestigious University-Enterprise Cooperation Alliance for Study in China, facilitated by Beijing Foreign Studies University (BFSU). Following a successful engagement at the job fair hosted by BFSU, this development marks a significant milestone in ARC Group’s commitment to fostering academic-industry collaboration.

This partnership signifies a mutual dedication to resource-sharing, event coordination, and conference hosting aimed at enhancing the synergy between academia and industry. ARC Group is honored to assume this pivotal role within the alliance, recognizing the vast potential it holds for facilitating meaningful connections and driving innovation.

On May 8th, ARC Group welcomed students from BFSU to its Beijing office for an enriching visit. This engagement provided students with invaluable insights into ARC Group’s operations and consulting expertise, offering a glimpse into the dynamics of the finance and consulting sectors.

Looking ahead, ARC Group remains steadfast in its pledge to facilitate opportunities for students within BFSU’s esteemed business school. The company is committed to nurturing a robust partnership with the university, with a shared vision of empowering students with the requisite knowledge, skills, and avenues for success in the dynamic landscape of the business world.

ARC Group’s collaboration with BFSU underscores its unwavering dedication to fostering academic excellence and industry relevance, exemplifying a synergistic approach towards shaping tomorrow’s business leaders.

 

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission